August 1, 2025

Glibenclamide in Aneurysmal Subarachnoid Hemorrhage: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

View Full Paper

Ask AI

Bookmark

This meta-analysis found no significant advantage of glibenclamide for improving outcomes in patients with aneurysmal subarachnoid hemorrhage.
Among four randomized controlled trials involving 290 patients, glibenclamide showed no significant effect on delayed cerebral ischemia or death.
Conducted as a systematic review adhering to PRISMA guidelines, analysis utilized RevMan software to assess outcomes across trials.
Findings underline the need for cautious interpretation due to potential publication bias in evaluating glibenclamide's efficacy.

Discussion

No takes yet. Share an insight, caveat, or question.

Systematic review indicates no significant advantage of glibenclamide on outcomes in aSAH patients, suggesting caution in use.

Alsubaiei et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark